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T lymphocytes of 8 patients with ovarian cancer were tar- 
geted to the tumor cells using F(ab’)2 fragments of a bispecific 
monoclonal antibody (bsAb), specific for CD3 (a component of 
the T lymphocyte receptor for antigen) and for the folate 
receptor MOv I8  (overexpressed by ovarian carcinoma cells) as 
part of a phase 1/11 study. Phase I (days 0 to 3) consisted of 
increasing intraperitoneal (i.p.) numbers (I 06-1 09) of bsAb- 
targeted T lymphocytes plus low-dose interleukin-2 (IL-2). 
Phase II (days 6 to 13, and 27 to 33) consisted of daily i.p. 
infusions of I O9 targeted T lymphocytes, 2 mg soluble bsAb, and 
low-dose IL-2. Using enzyme-linked immunosorbent assays 
(ELISA), human anti-mouse antibodies (HAMA) were detected 
in all patients: in the serum from day 13 onwards and in the 
peritoneal fluid from day 20 onwards. A significant proportion of 
the HAMA appeared to be directed against the idiotypes of the 
bsAb specific for CD3 and MOv18, as suggested by (I) the 
clearly higher ELSA titers against OC/TR bsAb as compared to 
those against a monoclonal antibody (MAb) with unrelated 
specificity, and (2) failure to abrogate the capacity of peritoneal 
fluid containing HAMA to block the binding of OC/TR bsAb to 
MOv18+ or CD3+ cells by absorption of human anti-mouse 
IgG-framework antibodies in peritoneal fluid to immobilized 
mouse IgG. The OC/TR-targeted cytolysis of the MOv18+ 
ovarian carcinoma cell line Igrov- I by autologous T lymphocytes 
was inhibited by peritoneal fluid samples containing relatively 
high HAMA titers. Such inhibitory activity was never detected 
at the start of phase II, but coincided with the last series of i.p. 
infusions of targeted T lymphocytes in 2 patients. 
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Mouse MAbs directed against tumor-associated antigens 
(TAA) and conjugated to radioisotopes, chemotherapeutic 
agents or toxins are increasingly being used for in vivo 
diagnosis and treatment of malignancies (Mach et al., 1981; 
Schroff et a/., 1985). The infusion of murine immunoglobulins 
(Ig) elicits human anti-mouse Ig antibody (HAMA) responses. 
Such HAMA responses have been reported in clinical studies 
of tumor imaging (Courtenay-Luck et al., 1986) and tumor 
therapy (Schroff et a/., 1985; Courtenay-Lucket al., 1988; Saleh 
eta/., 1993). HAMA responses develop over a wide dose range 
(ie.,  from < 1 mg to > 1 g) (Khaezali et al., 1988), and occur 
more frequently after repeated administrations of MAbs (Lind 
et al., 1991). Fab fragments of murine MAbs and genetically 
engineered mouse-human MAbs are less immunogenic than 
intact murine Ig molecules (reviewed by Khaezali et al., 1994). 
Initially, HAMA with specificities for the constant regions of 
murine Ig develop, followed by HAMA with anti-idiotypic 
specificities. These latter antibodies develop particularly well 
after multiple administrations of MAbs (Schroff et a/., 1985; 
Saleh et al., 1993). Adverse clinical reactions upon administra- 
tion of MAbs to patients with pre-existing HAMA are uncom- 
mon, but a highly increased clearance of the administered 
MAb is seen in such patients, which may prevent the MAbs 
from interacting with their target (Khazaeli et al., 1994). 
Targeting of the cytolytic activity of T lymphocytes against 
tumor cells can be achieved using bispecific monoclonal 
antibodies (bsAbs) which are directed against a T-cell activa- 
tion epitope on the one hand (eg., CD3) and a TAA on the 
other. Targeting of cytotoxic T lymphocytes (CTL) with bsAb 
results in selective destruction of tumor cells following MHC- 
unrestricted binding of the CTL to tumor cells (Segal and 
Snider 1989; Van Dijk er al., 1989). This approach has been 
effective in reducing or eliminating tumor in several mouse 
model systems (Segal and Snider, 1989), in human malignant 
glioma (Nitta et a/., 1990) and in ovarian carcicoma (Bolhuis et 
a/., 1992). The O C / T R  bsAb is specific for CD3 and MOv18 
(Mezzanzanica et al., 1988). MOv18 has been identified as the 
glycosyl-phosphatidyl-inositol (GP1)-anchored, high-affinity fo- 
late-binding protein gp38 (Coney et al., 1991), and is overex- 
pressed on ovarian carcinoma cells as compared to normal 
ovarian cells. The OC/TR bsAb was used as part of the 
intraperitoneal (i.p.) treatment of ovarian carcinoma in a 
phase-1/11 clinical trial (Bolhuis et al., 1992). Patients entered 
into this trial received 10 therapeutic i.p. infusions with 
O C / T R  and autologous OC/TR-targeted activated T lympho- 
cytes. This report concerns the kinetics of HAMA responses in 
these patients and the interference of HAMA with bsAb- 
targeted cytolysis. 
MATERIAL AND METHODS 
Clinical study 
Eight ovarian-carcinoma patients were treated with i.p. 
infusions of targeted T lymphocytes and the bsAb OC/TR in a 
phase-1/11 clinical trial. Patients with advanced epithelial 
ovarian carcinoma ( F I G 0  stage 111, MOvl8-positive tumor, 
and thickness of residual tumor lesions of less than 2 cm after 
debulking surgery), were eligible. T lymphocytes were acti- 
vated in vitro and expanded using phytohemagglutinin (PHA; 
Wellcome, Dartford, UK) and interleukin-2 (IL-2; Proleukin, 
Eurocetus, Amsterdam, The Netherlands) as described previ- 
ously (Lamers et a/.. 1992). The bsAb O C / T R  F(ab’)z frag- 
ments were produced by Centocor Europe (Leiden, The 
Netherlands). Prior to i.p. administration, the cultured T 
lymphocytes were incubated for 30 min at 37°C with OC/TR 
bsAb (I mg per lo6 to lo9 viable cells; Table I ) .  Thereafter, 
unbound bsAb was washed away in phase I but was not 
removed in phase 11, and 0.6 x 106IU IL-2 were added prior to 
administration in all cases. According to the schedule (Table I )  
the patients were to  receive 3 cycles of i.p. therapy of 
autologous OC/TR-labeled T lymphocytes, soluble OC/TR 
and IL-2 Thus, they should have received a total of 10 x lo9 
OC/TR-labeled T lymphocytes, 28 mg OC/TR bsAb and 
16.8 x lo6 IU IL-2 during phase 11. The actual treatment 
differed from schedule in 3 of the 8 patients. Patient 2 received 
a third therapeutic cycle from days 48 to 52 because her first 
therapeutic cycle was considered inadequate due to insuffi- 
cient fluid distribution in the peritoneal cavity. For patient 6, 
whom correspondence and reprint requests should be sent, at 
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the interval between phase I and the first therapeutic cycle of 
phase I1 was extended to 14 days because of slow in vitro 
expansion o f  the autologous T lymphocytes. Treatment of 
patient 8 was abrogated on day 28 (i.e., after the first day of the 
second therapeutic cycle) due to her poor clinical condition. 
Serum and peritoneal fluid samples were taken prior to the 
first infusion and on days 6, 13, 27, 34, 49, and around days 70 
and 100. Serum and peritoneal fluid samples were cleared 
from cells and debris by centrifugation and stored at -80°C 
until further investigation. 
Detection of human anti-mouse antibodies ( H A M )  
The presence of HAMA in serum and peritoneal fluid 
samples was assessed using a 2-step sandwich enzyme-linked 
immunosorbent assay (ELISA). As solid phase, F(ab’)2 frag- 
ments of the OCI’TR bsAb (IgGI/IgGI), of the 323/A3 MAb 
(an IgG,, K MAb with pan-carcinoma specificity; Edwards et 
al., 1986) and of the MOv18 MAb (IgGI, K) were used (all from 
Centocor Europe, Leiden). The tracer antibody was goat 
anti-human Fc(1gG) conjugated with alkaline phosphatase 
(Affipure; Jackson Immunotech, West Grove, PA) and the 
substrate was p-nxtrophenylphosphate disodium dissolved in 
2-amino-2-methyl-1-propanol (Sigma, St. Louis, MO) at pH 
10.3. The wells of 96-well microtiter plates (Nunc, Roskilde, 
Denmark) were coated with 2 pg of antibody in 50 pl of 0.1 M 
glycine. 0.5 mM EIITA, p H  8.5, for 16 hr at 4°C. After washing 
with PBS (pH 7.4), free binding sites on the matrix were 
blocked with 150 p.1 PBS containing 1% BSA, for 1 hr at 37°C. 
Thc assay samples; (80 pI/well), diluted in PBS + 1% BSA, 
were incubated for 2 hr at 37°C. The initial dilution was 1:20. A 
HAMA-positive serum and a pool of normal human sera were 
run with each assay plate as positive and negative controls, 
respectively. The plates were washed 5 times with PBS 
containing 0.1% Tween-20 and incubated with 75 pl/well of 
tracer antibody (diluted 1:2,000 in PBS + 1% BSA) for 1 hr at 
37°C. After washing with PBS + 0.1% Tween-20, the plates 
were incubated wii h 100 pl/well substrate for 30 rnin at 37”C, 
and the reaction was abrogated by adding 50 pI 3N NaOH. The 
optical density (OD) was read at 405 nm. The reciprocal 
dilution of the serum sample with OD405 = 1.0 was arbitrarily 
refcrred to as the HAMA titer. 
Removal of human antibodies to murine IgG from 
peritoneal fluid 
Human anti-murine IgG antibodies were removed from sera 
and peritoneal fluid by affinity absorption using mouse IgG 
(Sigma) coupled to Affi-gel 10 (BioRad, Richmond, CA). For 
coupling, 10 mg mouse IgG in 0.5 ml 1 M NaCI, 80 mM CaCI2 
and 0.1 M HEPES (pH 7.2), was incubated with 1 ml Affi-gel 
10 for 4 hr at 4°C on a roller bank. Residual reactive Affi-gel 
binding sites were blocked by incubation with 0.1 M ethanol- 
amine-HCI for 1 hr. For absorption of human antibodies to 
murine IgG, 1 ml peritoneal fluid was mixed with 0.25 ml of 
coupled Affi.-gel 10 and incubated for 16 hr at 4°C on a roller 
bank. Thereafter, the peritoneal fluid was separated from the 
Affi-gel 10 by centrifugation. This absorption procedure was 
repeated once with freshly coupled Affi-gel 10. The processed 
peritoneal fluid samples were tested for residual HAMA using 
thc ELISA described above. 
Flow cytometric assay of HAMA-mediated inhibition of OCITR 
bsAb binding to Igrov-I and DII  cells 
The MOv18+ ovarian carcinoma-derived cell line Igrov-1 
(Benard et al., 1985) and the CD3+, 4+, 8+,  TCRaP+ CTL 
clone D11 (Van de Griend et al., 1984) were used to analyze 
HAMA-mediated inhibition of binding of OC/TR bsAb to 
these cells. From each cell line, 50 p1 containing 0.50 x lo6 
cells were incubated for 30 rnin at 0°C with 50 pl of (1) PBS + 
1% BSA; (2) 1 pg,’ml OC/TR bsAb; (3) W6/32 (anti-HLA- 
A,B.C MAb obtained from SeraLab, Crawley Down, UK) 
diluted in PBS + 1% BSA, (4) HAMA containing peritoneal 
fluid (diluted 1:2 in PBS + 1% BSA); ( 5 )  same as (4), with 
OC/TR bsAb; and (6) same as (4), with W6/32 MAb added 30 
min prior to the assay. Thereafter, the cells were washed once 
and incubated with goat-anti-mouse Ig conjugated with phyco- 
erythrin (PE; Southern Biotechnology, Burlington, VA) for 
another 30 min at 0°C. After washing once, the cells were fixed 
in PBS containing 10 mg/ml paraformaldehyde and analyzed 
using a FACScan flow cytometer (Becton Dickinson, San Jose, 
CA). For data acquisition, list mode data of 10,000 cells per 
sample were obtained. In the analyses of those data, dead cells 
and cell fragments were excluded on the basis of their low 
forward light scatter signals, after which PE fluorescence 
characteristics were studied using histogram statistics. 
Cytotoxicity (CTX) assay 
Cytolytic activities were assessed in a standard 3-hr X r -  
release assay, using T lymphocytes from ovarian cancer pa- 
tients, activated and expanded using PHA + IL-2, and the 
CTL clone D11, specific for HLA-(33, as effector cells 
(Bolhuis and Van de  Griend, 1985). The ovarian carcinoma 
cell line Igrov-1 and the Epstein-Barr virus-transformed, 
HLA-Cw3+ lymphoblastoid cell line BSM served as the source 
of target cells. The CTX assay medium was RPMI-1640 
supplemented with 10% newborn bovine calf serum (GIBCO, 
Grand Island, NY). The effector cells were pre-incubated with 
OC/TR for 30 min at 37°C; 100 pg/rnl of OC/TR were 
sufficient for optimal targeting of cloned and bulk-cultured 
CTL (Mezzanzanica et al., 1988). In one experiment, chimeric 
F(ab’)2 OC/TR (chOC/TR; Centocor Europe), in which the 
murine constant part of the antibody was replaced by the 
corresponding human constant part, was used to target D11 
cells. Varying numbers of effector lymphocytes were seeded in 
triplicate in 96-well, round-bottomed microtiter plates (100 
pl/well), followed by 2,500 target cells in 100 p1 per well. The 
target cells were labeled with 100 pCi 51Cr per 0.5 x lo6 cells 
for 2 hr at 37°C. The effector to target (E:T) ratios used in most 
cases were 50,25,12 and 6:l. At the end of the 3-hr incubation 
period (37°C and 5% CO?), supernatants were collected and 
5’Cr release was measured in a gamma-counter. The percent- 
age of specific lysis was calculated according to standard 
formulas. The data were expressed as percentage specific lysis 
for each of the 4 E:T ratios tested. 
For analysis of the interference of HAMA in peritoneal fluid 
with in vitro OC/TR-mediated cytolytic activity, autologous T 
lymphocytes that had been activated and expanded using PHA 
and IL-2 were targeted with OC/TR F(ab’), as described 
above, and subsequently washed twice to remove unbound 
OC/TR. OC/TR-targeted or untargeted T lymphocytes were 
resuspended in undiluted, heat-inactivated (30 min at 56°C) 
peritoneal fluid samples. The target cells were resuspended in 
the corresponding peritoneal fluid samples. A similar CTX 
assay performed in CTX assay medium instead of peritoneal 
fluid served as positive control in each experiment, whilst CTX 
assays using untargeted T lymphocytes served as negative 
controls. 
RESULTS 
H A M  in serum and peritoneal fluid become detectable during 
therapy and contain anti-idiotypic antibodies 
HAMA became detectable in the serum and peritoneal fluid 
of all 8 patients during treatment (Fig. 1). Serum IgG antibod- 
ies reactive with OC/TR bsAb were first detectable after a 
median of 20 days (range 13 to 27) and reached their peak 
after a median of 49 days (range 27 to 70) after the start of 
phase I. The median peak serum titer was 107,000 (range 511 
to 1.4 x lo6). Serum IgG antibodies reactive with 3231A3 
showed similar kinetics but reached lower titers (median peak 
serum titer, 12,000 [range 50 to 45,0001). Thus, it appeared 
452 
6 
10 i Patient7 
5 '  
10 I 
10' ; 
LAMERS ETAL.  
I Patient 8 
I 
I 
I 
I 
I 
I 
- 0h;l 8 00 B 
1 o6 
1 o5 
1 o4 
3 
10 
1 o2 
Patient 1 
1 
I 
1 1  I N  N I N  I I 10 ' " " " ' ' ' " ' ~ ' ~  " " " " " " '  " " " " " " " " " " " " " '  
6 
10 
5 
10 
4 
10 
3 
10 
2 $) 10 
U .- - ,  
Patient 3 I 
4 10' 
I 5 lo6 Patient 5 
I I 
I 
i 
~ 
1 o5 
4 
10 
103 
2 
10 
1 BEl RE' 3 
10 " 1  1 '  " '  " 1  " ' ' 1  ' 1  ' I " ' ' '  ' ' ' " ' 1  ' " " " ' 1 ' '  ' 1 '  " ' " ' 
Patient 2 r 
d 
i Patient 6 I 
I 
I 
0 n o  
Days After Start of Phase I Therapy 
FIGURE 1- HAMA titers in sequential serum and peritoneal fluid samples from 8 patients. For each patient, serum titers are set out in 
the left panel and peritoneal fluid titers in the right panel. HAMA titers against OCiTR bsAb are represented by closed symbols 
connected by bold lines; those against 3231A3 MAb (with specificity unrelated to that of OC/TR) by open symbols connected by thin 
lines. Hatched boxes represent time periods during which immunotherapy (1 phase-I cycle, followed by 2 to 3 phase-I1 cycles) was 
administered. Logarithmic scales were used for the Y axes in order to compress the figures. 
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that a significant component of HAMA was directed against 
the idiotypes of OCITR bsAb. 
The kinetics o f  IgG antibody titers reactive with OCiTR 
bsAb o r  3231A3 MAb in peritoneal fluid paralleled those in 
the serum. HAMA reactive with OC/TR bsAb were first 
detectable after a median of 22 days (range 20 to 34) and 
reached their peak after a median of 48 days (range 27 to 70) 
after the start of phase I. The median peak titer was 27,000 
(range 200 to 1.6 x loh). As in the serum, the titers of HAMA 
reactive with 323iA3 were lower than those reactive with 
OC/TR bsAb (median peak titer, 1,075 [range 45 to 50,0001). 
Thc fluctuations of HAMA titers in the peritoneal fluid 
observed in patients 2 ,4  and 5 may have been caused in part by 
dilution by the i.p. infusions of targeted T lymphocytes 
(2 x 500 ml daily) and by the rinsing of the peritoneal cavity 
with saline betwcen the 2 therapeutic cycles. 
Further evidence that HAMA by and large comprised 
anti-idiotypic antibodies reactive with OCiTR bsAb was ob- 
tained by the observation that removal of human anti-mouse 
IgG antibodies by absorption to murine IgG coupled to 
Affi-gel 10 from the day-48 peritoneal fluid sample of patient 2 
did not abrogate its capacity to block the binding of OCiTR 
bsAb to Igrov-1 ovarian carcinoma cells or to the CTL clone 
D11. The 2-fold absorption procedure of this specimen with 
mouse IgCi coupled to Affi-gel 10 led to a 98% reduction in 
titer of antibodies reactive with 323iA3 MAb ( ie . ,  from 4,200 
to 70), whilst only a 43% reduction in titer of antibodies 
reactive with OC/TR bsAb was seen (k, from 11,300 to 
6,400). Figure 2 shows that addition of OC/TR bsAb to both 
unabsorbed (upper panels) and absorbed (lower panels) peri- 
toneal fluid, 30 rnin prior to incubation with D11 or Igrov-1 
cells, led to clear reductions in the levels of reactivity with 
these cell types (i.e., approaching those of the respective 
peritoneal fluid samples in the absence of OCiTR bsAb) as 
compared to the levels of reactivity obtained with OC/TR 
CTL D11 
OCnR bsAb W6l32 anti-HLA-A,B,C mAb 
-INDUCED CYTOLYSIS 453 
added to PBS + 1% BSA. In contrast, addition of W6i32 MAb 
with specificity different from that of OCiTR (i.e.. anti-HLA- 
A,B,C) to unabsorbed peritoneal fluid led only to partial 
reductions in the levels of reactivity with D11 and Igrov-1 cells 
as compared to the levels of reactivity obtained with W6/32 
added to PBS + 1 % BSA (Fig. 2, upper panels). Moreover, the 
reactivity of W6132 MAb, following addition to absorbed 
peritoneal fluid, with D11 and Igrov-1 cells was only slightly 
lower than that of W6132 added to PBS + 1% BSA (Fig. 2, 
lower panels). These results confirmed that HAMA comprised 
both anti-murine IgG-framework and anti-idiotypic antibodies 
reactive with OC/TR bsAb. 
Interaction between HAMA and OCiTR-targeted cytolysis of 
Igrov-1 ovarian carcinoma cells 
Since MOv18 is shed, although to a limited extent, from the 
surface of fresh ovarian tumor cells and cell lines (Miotti et a/ . ,  
1992), ascitic or peritoneal fluid samples from such patients 
may contain free MOv18 glycoproteins which may interfere 
with in vitro assays of OCiTR-targeted cytolysis. However, we 
observed that the levels of bsAb-targeted cytolysis of Igrov-1 
cells in the presence of peritoneal fluid obtained prior to 
treatment (day 0) were similar to those in the presence of 
standard assay medium in all of the 7 patients investigated in 
this respect (Fig. 3). 
Next, we studied whether or not peritoneal fluid samples 
containing HAMA could inhibit OCiTR-targeted cytolysis of 
Igrov-1 cells. Inhibition was detected in peritoneal fluid 
samples of 6 of the 8 patients, and particularly in samples with 
relatively high HAMA titers (Fig. 3). Seven of 8 peritoneal 
fluid samples with HAMA titers of 5,778 or more inhibited 
OC/TR-targeted cytolysis of Igrov-1 cells lis. only 1 of 20 
samples with HAMA titers <5,778 (Fisher’s exact test, 
p < 0.001). Inhibition was only detected after completion of 
phase I1 in 4 patients (1 ,4 ,6  and 7), but coincided with therapy 
Igrov-1 Ovarian Carcinoma Cell Line 
OCiTR bsAb W6l32 anti-HLA-A,B.C mAb 
Log fluorescence intensity 
FIGURE 2 -- Interaction between OCiTR bsAb and unabsorbed (upper panels) or mouse IgG-absorbed (lower panels) peritoneal fluid 
containing HAMA led to clear reductions in the levels of OCiTR reactivities with CTL D11 and the Igrov-1 ovarian carcinoma cell line. 
In contrast, reactivity of W6132 MAb (anti-HLA-A,B,C) with those cell types was only partially or minimally blocked by interaction with 
unabsorbed or absorbed peritoneal fluid, respectively. The day-48 peritoneal fluid sample of patient 2 was used. Prior to absorption, the 
HAMA titer against OCiTR bsAb was 11,300 and the titer against 3231A3 MAb was 4,200. Following absorption, these titers were 6,400 
and 70, respectively. Uninterrupted lines: reactivity of D11 or Igrov-1 cells with OCiTR or W6/32, visualized using GAMiIgGIPE; 
interrupted lines: reactivity of D11 or Igrov-1 cells with OC/TR or W6/32 that had been pre-incubated with unabsorbed or absorbed 
peritoneal fluid; dotted lines; reactivity of D11 or Igrov-1 cells with GAMIIgGIPE after incubation with unabsorbed or absorbed 
peritoneal fluid. 
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FIGURE 3 - Interaction between HAMA in sequential peritoneal fluid samples and OC/TR-targeted cytolysis of Igrov-1 ovarian 
carcinoma cells by autologous T lymphocytes activated and expanded using PHA + IL-2. The sampling time point of each peritoneal 
fluid sample is indicated as day relative to start of phase I .  Arrows indicate the end of phase 11. The HAMA titer against OC/TR bsAb 
(ELISA assay) is indicated between brackets for each peritoneal fluid sample. CTX assays using OC/TR-targeted T lymphocytes as 
effector cells are represented by closed symbols connected by bold lines; the corresponding assays using untargeted T lymphocytes are 
represented by open symbols connected by thin lines. CTX assays performed in CTX assay medium (indicated by “Med”) instead of 
peritoneal fluid served as positive controls for OC/TR-targeted cytolysis of Igrov-1 cells in each experiment. The E:T ratios in assays 
designated 3-25 were 3, 6 ,  12 and 25:1, respectively; those in assays designated 6-50 were 6, 12, 25 and 50, respectively. All peritoneal 
fluid samples were heat-inactivated (30 min at 56°C) prior to the CTX assays. 
HAMA INHIBITS bsAb-INDUCED CYTOLYSIS 
40 
20 
455 
:::r 
- 
TABLE I - TREATMENT SCHEDULE 
Phase Dav of theraov 1-l Infusion'.? 2nd Infusion'  
I IL2 106 Lv x OC/TR3 + IL2 
107Li x OC/TR3 + IL2 
lox Ly x OC/TR? + IL2 
loq Ly x OC/TR3 + IL2 
IL2 
IL2 
IL2 
I1 (lst herapeutic cycle) 6, 7. 8, 9, 10 10' Ly x OC/TRJ + IL2 IL2 + OCiTR 
11,12 IL2 + OC/TR IL2 + OCiTR 
I1 (2nd therapeutic cycle) 27,28,29,30,31 loq Ly x OC/TR4 + IL2 IL2 + OC/TR 
32.33 IL2 + OC/TR IL2 + OCiTR 
'The lst infusion was administered at 12 A.M. and the Znd infusion at 8 P.M.- 2Ly x OCITR, autologous T 
lymphocytes targeted with OC/TR bsAb; IL-2,0.6 x lo6 IU IL-2; OC/TR, 1 mg soluble OC/TR bsAb. All 
infusions were given in 500 ml of Ringer's lacate solution supplemented with 1% human serum 
albumin.-?Unbound OC/TR bsAb was washed a~ay.-~Unbound OC/TR bsAb was not removed. 
in 2 patients (2 an3  5). Patient 2 received a third therapeutic 
cycle (days 48-52). Peritoneal fluid obtained at days 48 and 54 
completely inhibited OC/TR-targeted cytolysis of Igrov-1 
cells. The day-27 sample of patient 5, obtained immediately 
before the start of the second phase-I1 therapeutic cycle 
(Table I), also inhibited OC/TR-targeted cytolysis of Igrov-1 
cells. This sample had an exceptionally high HAMA titer (i.e., 
29,550) in comparison to  the day 27 samples of other patients 
(k., ranging between < 20 and 267; patients 1, 2, 6, 7 and 8). 
The increased lysis of Igrov-1 target cells by untargeted T 
lymphocytes in patient 1 (days 27 and 34), patient 4 (days 13), 
patient 5 (days 13 and 34), patient 6 (day 27), patient 7 (days 13 
and 27) and patient 8 (days 13 and 30) was caused by the 
presence of free OC/TR bsAb in those peritoneal fluid 
samples. This presence was detected by incubation of D11 and 
Igrov-1 cells in peritoneal fluid followed by indirect immunoflu- 
orescence (data not shown). 
Finally, we analyzed the interaction between HAMA in 
peritoneal fluid samples, and (1) OC/TR-targeted cytolysis of 
Igrov-1 cells; (2) chOC/TR-targeted cytolysis of Igrov-1 cells, 
and (3) untargeted, HLA-Cw3-specific cytolysis of BSM cells, 
by D11 effector cells (Fig. 4). Three peritoneal fluid specimens 
were selected: one from patient 1, obtained on day 69 (HAMA 
titers [ELISA assay] against OC/TR bsAb, 896,000; against 
3231A3 MAb, 17,000); one from patient 2, obtained on day 48 
and diluted 1:4 in ClTX medium (final HAMA titers 2,093 and 
236, respectively); and one from patient 5, obtained on day 48 
(HAMA titers 193,400 and 23,500, respectively). First, all 3 
samples complete1,y inhibited OC/TR-targeted cytolysis of 
Igrov-1 cells by the CTL clone D11 (Fig. 4, upper panel). A 
combination of human anti-idiotypic and anti-murine Ig- 
framework antibodies may be responsible for this inhibition. 
Second, the possible inhibitory effect of HAMA against the 
murine CH and CL domains was excluded in the subsequent 
assay in which the D11 cells were targeted using chOC/TR 
(Fig. 4, middle panel). The cytolysis of Igrov-1 cells by 
chOC/TR-targeted D11 cells was still completely inhibited in 
the assays with the highest HAMA concentrations, i x . ,  those 
carried out using the peritoneal fluid samples of patients 1 and 
5, whilst partial inhibition was seen in the assay with the lowest 
HAMA concentration, i.e., the one carried out in the 1:4 
diluted peritoneal fluid from patient 2. This observation 
indicates that the inhibition of OC/TR-targeted cytolytic 
activity by patient 2's peritoneal fluid was partly due to 
anti-murine CH and/or CL antibodies. Third, HAMA had no 
effect on untargetecl, HLA-Cw3-specific cytolysis of BSM cells 
by the D11 effector cells (Fig. 4, lower panel). 
DISCUSSION 
We have studied the kinetics of HAMA responses and the 
interference of  HAMA with OC/TR bsAb-targeted cytolysis 
3-25 3-25 3-25 3-25 
E:T Ratio 
FIGURE 4 - Interaction between HAMA in peritoneal fluid and 
OC/TR-targeted (upper panel), chOC/TR-targeted (central panel) 
and HLA-Cw3-specific (lower panel) lysis by D11 CTL. The 
following peritoneal fluid samples were used: patient 1, day 69 
(HAMA titers [ELISA assay] against OC/TR bsAb, 896,000; 
against 323/A3 MAb, 17,000); patient 2, day 48, 1:4 diluted 
(HAMA titers after 1:4 dilution, 2,093 and 236, respectively); and 
patient 5, day 48 (HAMA titers 193,400 and 23,500, respectively). 
CTX assays using OC/TR-targeted or chOC/TR-targeted D11 
CTL as effector cells are represented by closed symbols connected 
by bold lines; assays using untargeted D11 CTL are represented by 
open symbols connected by thin lines. CTX assays performed in 
CTX assay medium (indicated by "Medium") instead of perito- 
neal fluid served as positive controls in  each experiment. The E:T 
ratios were 3, 6, 12 and 25:1, respectively. All peritoneal fluid 
samples were heat-inactivated (30 min at 56°C) prior to the CTX 
assays. 
in 8 ovarian carcinoma patients receiving phase-1/11 i.p. 
immunotherapy using OC/TR-targeted lymphocytes, soluble 
OC/TR bsAb and low-dose IL-2. HAMA were detected using 
ELISA in serum and peritoneal fluid samples of all 8 patients 
from 2 and 3 weeks following start of therapy onwards, 
respectively, and reached peak levels at 7 weeks. These results 
are consistent with published data on the serum kinetics of 
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primary IgG HAMA responses following intravenous (Courte- 
nay-Luck et d., 1986) or intraperitoneal (Maher et al., 1992) 
administrations. A significant part of the HAMA appeared to 
be directed against the idiotypes of OCiTR bsAb specific for 
CD3 and MOv18, as suggested by (1) the clearly higher ELISA 
titers against OC/TR bsAb compared to those against a MAb 
with unrelated specificity, and (2) the failure to  abrogate the 
capacity of peritoneal fluid to block the binding of OCiTR 
bsAb to MOv18+ or CD3+ cells by absorption of human 
anti-mouse IgG-framework antibodies in peritoneal fluid to  
immobilized mouse IgG. Indeed, anti-idiotypic HAMA re- 
sponses have been observed in particular after repeated M A b  
administrations (Schroff et al., 1985; Courtenay-Luck et al., 
1988; Saleh et al., 1993). 
The specificity of HAMA for the complementarity-determin- 
ing region (CDR) of M A b  has been demonstrated previously 
using inhibition of antigen binding (Traub et al., 1988) or 
inhibition of anti-idiotypic antibody binding to  that M A b  
(Chattopadhyay et al., 1991). We have followed the first 
approach (Fig. 2). An important observation was that perito- 
neal fluid samples with relatively high HAMA titers inhibit in 
vitro OCiTR-targeted cytolysis of ovarian carcinoma cells (Fig. 
3). This inhibitory activity was never detected at  the start of the 
therapeutic infusions of OCiTR-targeted T lymphocytes (Le., 
phase 11), but became detectable during phase I1 in 2 patients. 
This result suggests that  HAMA may interfere with the goal of 
therapy, i.e.. the in vivo destruction of tumor cells by bsAb- 
targeted T lymphocytes. 
Strategies for overcoming the immunogenicity problem 
include the use of murine-human antibody constructs: chi- 
meric MAb, composed of murine VH and  VL regions combined 
with human CH and CL regions, or CDR-grafted MAb, which 
consist not only of human constant regions but also of the 
framework of human VH and V L  regions (reviewed by Khazaeli 
et al., 1994). Although such molecules are  probably less 
immunogenic than their entirely murine counterparts, they 
still elicit anti-idiotypic HAMA responses and, hence, antibod- 
ies with different anti-tumor idiotypes need to be used in the 
case of prolonged or repeated therapeutic interventions using 
bsAb-targeted T lymphocytes. An alternative to the use of 
autologous bsAb-targeted T lymphocytes is offered by geneti- 
cally engineered T lymphocytes endowed with receptors spe- 
cific for tumor-associated antigens (Hwu et d., 1993), which 
may be less immunogenic. 
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